When to Invest in Brand (And Why Timing Is Everything in MedTech)
Part I: The quiet question shaping MedTech trajectories.
Every MedTech founder eventually hits a pressure point that has nothing to do with reimbursement strategy, regulatory timelines, or clinical data.
It’s this: “When should we invest in brand?”
Not the logo. Not the booth backdrop. Not the marketing collateral you scramble to build before a conference.
But the deeper infrastructure that separates companies that scale from those that stall:
A credible strategic narrative
Evidence-aligned messaging
A differentiated value proposition
A visual + verbal identity that communicates maturity
A creative platform that works across clinicians, investors, partners, and payers
Ask five founders and you’ll get five different answers. Ask five investors and they’ll say, “It depends.” Ask five clinicians and they’ll tell you they absolutely notice when a company doesn’t have it.
But across experience and industry data, a clear pattern emerges:
Most MedTech teams wait too long.
Brand strategy should start in the late Seed to early Series A timeframe — long before polish, long before commercialization, long before a full identity system makes sense. And the full creative platform typically needs to be in place by the late Series A to Series B timeframe.
And waiting past Series B? That’s when companies lose control of their narrative, lose commercial momentum, and unintentionally give competitors the advantage.
Brand isn’t cosmetic in MedTech. It’s commercial clarity. It’s trust. It’s your runway.
Coming soon: Part 2. Why brand strategy needs to start earlier than most founders think.